← Back to Search

Breast Cancer for Breast Cancer

N/A
Waitlist Available
Research Sponsored by Anne Arundel Health System Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

Breast cancer biomarkers are usually performed on core needle biopsy (CNB) specimens and are not routinely repeated on surgical specimens (SS). However, preliminary data suggests that testing these biomarkers, on SS when compared to CNB samples can lead to different results. Our hypothesis is that The aim of this study is to identify a group of women with invasive breast cancer who may benefit from additional HER2 testing on their SS to ensure that areas of HER2 amplification are not missed. Another aim is to determine whether further HER2 testing on the SS in select patients would lead to changes in breast cancer treatment options.

Eligible Conditions
  • Breast Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Benefit of additional Her2 testing

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Breast CancerExperimental Treatment1 Intervention
Post Surgical Her2 testing

Find a Location

Who is running the clinical trial?

Genentech, Inc.Industry Sponsor
1,563 Previous Clinical Trials
569,979 Total Patients Enrolled
96 Trials studying Breast Cancer
23,108 Patients Enrolled for Breast Cancer
Anne Arundel Health System Research InstituteLead Sponsor
7 Previous Clinical Trials
651 Total Patients Enrolled
~9 spots leftby Nov 2025